Leerink Partnrs Forecasts DexCom’s Q1 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for DexCom in a report released on Friday, February 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of $0.31 per share for the quarter, up from their prior forecast of $0.30. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.51 EPS and FY2029 earnings at $3.67 EPS.

DXCM has been the subject of a number of other reports. Wells Fargo & Company lifted their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Stock Up 1.6 %

NASDAQ DXCM opened at $90.53 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a 50 day moving average of $82.65 and a 200-day moving average of $75.62. The company has a market cap of $35.36 billion, a price-to-earnings ratio of 54.21, a PEG ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently made changes to their positions in the stock. Forvis Mazars Wealth Advisors LLC raised its holdings in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares during the period. Principal Securities Inc. raised its holdings in shares of DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after acquiring an additional 135 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its holdings in shares of DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company’s stock worth $766,000 after acquiring an additional 140 shares during the last quarter. Finally, Level Four Advisory Services LLC raised its holdings in shares of DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock worth $1,026,000 after acquiring an additional 150 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.